BEDMINSTER, N.J.--(BUSINESS WIRE)--
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will
report its second quarter 2012 financial results on Wednesday, August 1,
2012 at approximately 4:30 p.m. ET. The press release will be followed
by a conference call and webcast at 5:00 p.m. ET.
To participate in the conference call, dial (866) 730-5762 and use
passcode 76762943. International callers may dial (857) 350-1586, using
the same passcode. In addition, a live audio of the conference call will
be available over the Internet. Interested parties can access the event
through the investors' calendar of events page on the NPS website, http://www.npsp.com/page/calendar.
If you are unable to participate in the live call, a replay will be
available at (888) 286-8010, with passcode 81581902 until midnight ET,
August 15, 2012. International callers may access the replay by dialing
(617) 801-6888, using the same passcode. The webcast will also be
available through the NPS website for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing
orphan products to patients with rare disorders and few, if any,
therapeutic options. NPS is advancing two late-stage registration
programs. A New Drug Application is undergoing FDA review for Gattex®
(teduglutide) as a treatment for adult short bowel syndrome (SBS) and a
Phase 3 registration study has been completed for Natpara? (recombinant
human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism.
NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790
and NPSP795, with potential application in rare disorders involving
increased calcium receptor activity, such as autosomal dominant
hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary
programs with a royalty-based portfolio of products and product
candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen
Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda
Pharmaceutical Company Limited).
